Clinical Trial Details
EORTC-26071-22072-BTG-ROG
Back to Clinical Trials Database
Cilengitide in subjects with newly diagnosed glioblastoma and methylated MGMT promoter gene- a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC)
| Trial Status | LT-FU ongoing |
|---|---|
| Dates |
Date of activation: 11-Aug-2008 Date Step1 close: 10-May-2011 Date Step2 close: 06-Jun-2011 |
| Data management at EORTC | No |
| Design |
Phase 3 Randomized open label |
| Targeted Sample size | All Groups: 504 |
| Treatment |
Drug Temozolomide, Cilengitide |
| Study Staff |
Vassilis Golfinopoulos (Clinical Research Physician) , EORTC Headquarters, Brussels Thierry Gorlia (Statistician) , EORTC Headquarters, Brussels Marie-Ange Lentz (Data Manager) , EORTC Headquarters, Brussels Sara Meloen (Pharmacovigilance Manager) , EORTC Headquarters, Brussels |
| Type of cancer | Brain |
| Participating groups |
EORTC Brain Tumor Group EORTC Radiation Oncology Group |
| Protocol summary | http://clinicaltrials.gov/study/NCT00689221 |
| NCT number | NCT00689221 |
| EudraCT | 2007-004344-78 |
| Financial Support | Fully supported |
